1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.

1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.

Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.

The present invention relates to the synthesis of new classes of sunscreen agents, the usage of such sunscreen agents in sunscreen formulations aiming at reduction of sunscreen agents' skin penetration, and a formulation technology using existing sunscreen agents aiming at reduction of sunscreen agents' skin penetration, therefore improving the bio-safety of the sunscreen products.

The present invention relates to the synthesis of new classes of sunscreen agents, the usage of such sunscreen agents in sunscreen formulations aiming at reduction of sunscreen agents' skin penetration, and a formulation technology using existing sunscreen agents aiming at reduction of sunscreen agents' skin penetration, therefore improving the bio-safety of the sunscreen products.

The present invention relates to new polymorphs of LXRβ agonists which exhibit improved physical properties. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of an LXRβ agonist, as well as methods of treating cancer including administration of a formulation including an LXRβ agonist to a subject in need thereof.

The present invention is directed to various polycyclic compounds and methods of using these compounds to treat a variety of diseases including metabolic diseases such as obesity, diabetes, nonalcoholic fatty liver disease; cardiovascular diseases such as hypertension and stroke; neurological diseases, male infertility, muscular disorders, and immune disorders.

The present invention is directed to various polycyclic compounds and methods of using these compounds to treat a variety of diseases including metabolic diseases such as obesity, diabetes, nonalcoholic fatty liver disease; cardiovascular diseases such as hypertension and stroke; neurological diseases, male infertility, muscular disorders, and immune disorders.

Compounds, pharmaceutically acceptable salts, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL2, as well as methods of treatment for diseases involving the biological activity of CCL2.

Compounds, pharmaceutically acceptable salts, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL2, as well as methods of treatment for diseases involving the biological activity of CCL2.